Summary："ADMA Biologics Investors Urged to Act Fast Before Critical Deadline in Securities Lawsuit"NEW YORK,

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

"ADMA Biologics Investors Urged to Act Fast Before Critical Deadline in Securities Lawsuit"

NEW YORK, June 19, 2026 (GLOBE NEWSWIRE) -- Investors who purchased securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024, and March 25, 2026, are being reminded by the Rosen Law Firm, a global investor rights law firm, to take immediate action before the impending deadline in a securities class action lawsuit. The Class Period, as defined by the lawsuit, encompasses a critical timeframe during which investors may have been misled regarding the company's financial health and operational performance.

Key developments in the lawsuit have highlighted significant concerns regarding ADMA Biologics' transparency and disclosure practices during the Class Period. According to the lawsuit, investors may have suffered substantial losses due to allegedly false or misleading statements made by the company. As the deadline for potential lead plaintiffs to come forward approaches, investors are encouraged to review their options carefully and consider participating in the lawsuit to potentially recover their losses.

The biotechnology sector, in which ADMA Biologics operates, is characterized by intense scrutiny and high stakes, particularly concerning the accuracy and timeliness of corporate disclosures. The lawsuit against ADMA Biologics underscores the importance of rigorous compliance with securities laws and regulations. Industry analysts are closely watching the developments in this case, as it may have broader implications for corporate governance and investor protection within the biotech industry.

As the securities class action lawsuit against ADMA Biologics progresses, investors and market observers alike are keenly awaiting further developments. The outcome of this case could potentially impact the company's stock performance and influence investor confidence in the biotech sector more broadly. Investors who believe they may have been affected are advised to act swiftly to protect their interests.

In conclusion, the impending deadline in the securities lawsuit against ADMA Biologics presents a critical juncture for investors who purchased securities during the specified Class Period. With the Rosen Law Firm leading the charge, investors are urged to seek professional advice and consider their options for potential recovery of losses. As the case unfolds, its implications for corporate accountability and investor rights in the biotechnology industry will be closely monitored.